As of 2025-04-21, the Intrinsic Value of Harmony Biosciences Holdings Inc (HRMY) is 57.44 USD. This HRMY valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 28.46 USD, the upside of Harmony Biosciences Holdings Inc is 101.80%.
The range of the Intrinsic Value is 41.28 - 104.79 USD
Based on its market price of 28.46 USD and our intrinsic valuation, Harmony Biosciences Holdings Inc (HRMY) is undervalued by 101.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 41.28 - 104.79 | 57.44 | 101.8% |
| DCF (Growth 10y) | 46.63 - 112.62 | 63.59 | 123.4% |
| DCF (EBITDA 5y) | 32.37 - 38.54 | 34.66 | 21.8% |
| DCF (EBITDA 10y) | 38.61 - 48.20 | 42.47 | 49.2% |
| Fair Value | 63.38 - 63.38 | 63.38 | 122.69% |
| P/E | 35.39 - 65.57 | 50.59 | 77.8% |
| EV/EBITDA | 27.52 - 35.16 | 30.37 | 6.7% |
| EPV | 31.15 - 42.20 | 36.67 | 28.9% |
| DDM - Stable | 24.25 - 83.90 | 54.07 | 90.0% |
| DDM - Multi | 29.72 - 81.95 | 43.86 | 54.1% |
| Market Cap (mil) | 1,633.32 |
| Beta | 1.17 |
| Outstanding shares (mil) | 57.39 |
| Enterprise Value (mil) | 1,359.58 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.02% |
| Cost of Debt | 7.00% |
| WACC | 7.76% |